| 2215-CL-0301 | A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation | Leber, Dr Brian | Open | NCT02421939 |
| MEDALIST | A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536-MDS-001) Versus Placebo for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects with Ring Sideroblasts Who Require Red Blood Cell Transfusions (MEDALIST) | Leber, Dr Brian | Open | NCT02631070 |
| M15-531 | A Randomized Phase 2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Combination with Azacitidine Compared with Azacitidine Alone in Subjects with Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS) | Leber, Dr Brian | Open | NCT02942290 |
| AZA-MDS-003 | A phase 3, multicentre, randomized, double-blind study to compare with efficacy and safety of oral azacitidine plus best supportive care versus placebo plus best supportive care in subjects with red blood cell transfusion-dependent anemia and thrombocytopenia due to IPSS lower-risk myelodysplatic syndromes | Leber, Dr Brian | Open | NCT01566695 |
| INSPIRE | A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent | Leber, Dr Brian | Open | NCT02562443 |
| OZM-056 | Treatment-free Remission Accomplished with Dasatinib in Patients with CML | Leber, Dr Brian | Open | NCT02268370 |
| ASTRAL 3 | A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents | Leber, Dr Brian | Open | NCT02907359 |
| M15-550 | Open-label, single arm, phase 3b, multi-center study evaluating the efficacy of Venetoclax (ABT-199) in relapsed/refractory subjects with chronic lymphocytic leukemia (CLL) including those with the 17p deletion or TP53 mutation OR those who are refractory or intolerant to B-cell receptor inhibitors | Leber, Dr Brian | Open | NCT02756611 |
| WO29519 | A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PHASE III STUDY OF IDASANUTLIN, AN MDM2 ANTAGONIST, WITH CYTARABINE VERSUS CYTARABINE PLUS PLACEBO IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) | Leber, Dr Brian | Open | NCT02545283 |
| LY.17 | A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMA | Fraser, Dr Graeme | On hold | NCT02436707 |
Find a Trial
Contact Us